PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11524551

Sarcoma.

R Maki
View original source ↗Export metadata ↓

Abstract

ASCO 2001 was a banner year for innovative systemic therapy for sarcomas. Imatinib mesylate (STI571, Gleevec) shows clear activity not only in chronic myelogenous leukemia, for which the drug received Food and Drug Administration approval, but also in gastrointestinal stromal tumors as well, by virtue of imatinib mesylate binding to the abl, kit, and platelet-derived growth factor receptor tyrosine kinases. Ecteinascidin-743 (ET-743) demonstrates activity against a fraction of other soft-tissue sarcomas. Gemcitabine-based regimens show at least some activity against a subset of soft-tissue sarcomas. Given the lack of new agents for sarcoma therapy since the development of ifosfamide, these studies give hope that the term "effective systemic therapy for sarcoma" might become a reality.

Explore related subjects

Antineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsClinical Trials as TopicHumansSarcomaJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Maki. 2001. Sarcoma.. https://doi.org/10.1634/theoncologist.6-4-333

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

B-Cell lymphoproliferative disorder not associated with Epstein-Barr Virus in a child with relapsed acute lymphoblastic leukemia.

Lymphoproliferative disorder (LPD) is described in only a few children receiving chemotherapy for cancer. In all of them, an association between LPD and EBV (Epstein-Barr Virus) was found. We report on a patient who developed LPD not associated with EBV while receiving chemotherapy for relapsed acute lymphoblastic leukemia (ALL). Despite discontinuation of chemotherapy, administration of intravenous immunoglobulins and surgery the patient died. Growing experience with this disorder may allow better treatment options in the future and will show whether LPD not associated with EBV requires different therapeutic strategies.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed2002

Synergistic inhibitory effects of transplatin and beta-hydroxyisovalerylshikon on carcinoma A431 cells involve epidermal growth factor receptor.

Treatment of human epidermoid carcinoma A431 cells with transplatin (trans-DDP) and beta-hydroxyisovalerylshikon (beta-HIVS) together had a strong inhibitory effect on A431 cells. By contrast, trans-DDP and beta-HIVS by themselves, at the same respective concentrations, had practically no effect. The tyrosine kinase activities of v-Src and epidermal growth factor (EGFR) were inhibited by each of the two agents alone and strongly inhibited by combination. The observed synergistic inhibitory effect on the growth of A431 cells might have resulted from the inhibition of EGFR by trans-DDP, as well as by beta-HIVS.

Antineoplastic Combined Chemotherapy Protocols↗